NS-2359
Source: Wikipedia, the free encyclopedia.
Chemical compound
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
JSmol) | |
| |
(verify) |
NS-2359 (GSK-372475) is a
phase I clinical trial exploring the effect of NS-2359 on cocaine-dependent individuals was completed in 2002.[5]
See also
References
- ^ a b "NeuroSearch announces the results of Phase II Proof of Concept studies with NS2359 in depression". NeuroSearch.
- S2CID 9365152.
- PMID 18554401.
- ^ Clinical trial number NCT00467428 for "Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder" at ClinicalTrials.gov
- ^ Clinical trial number NCT00032916 for "Interaction Study With NS2359 and Cocaine in Cocaine Experienced Volunteers" at ClinicalTrials.gov
2-Carboxymethyl Esters | |
---|---|
(3,4-Disubstituted Phenyl)-tropanes | |
Arylcarboxy | |
Carboxyalkyl | |
Acyl | |
β,α Stereochemistry | |
α,β Stereochemistry | |
Heterocycles: 3-Substituted-isoxazol-5-yl | |
Heterocycles: 3-Substituted-1,2,4-oxadiazole | |
N-alkyl |
|
N-replaced (S,O,C) | |
Irreversible |
|
Nortropanes (N-demethylated) |
Retrieved from "https://en.wikipedia.org/w/index.php?title=NS-2359&oldid=1214973568"